VVOS (vivoslife.com) צמיחת רווח למניה השנה

Stable demand for apnea therapy gives Vivos Therapeutics (VVOS) defensive qualities, which is reflected in the price action. The final annual EPS growth rate shows a peak, after which the 37.90 indicator determines the parameter's status. Diversification through a clinic network mitigates risks, while a neutral geopolitical backdrop ensures the steady growth of medical system sales in the US without the impact of trade restrictions.

This metric is calculated as the relative change in net income per share for the current period compared to the same period last year. The metric determines the dynamics of capital generation for shareholders, revealing the pace of business scaling. For Vivos Therapeutics (VVOS), this growth depends on the expansion of non-invasive devices within the respiratory medicine market. Analyzing the EPS YoY percentage shift allows for an assessment of product commercialization efficiency. A steady rise on this chart confirms the resilience of the business model.